Why smart investors are staying out of Pets at Home right now

Pets at Home shares rally on genuine retail progress, yet at 199.80p the market is underpricing the risk that stabilisation proves temporary.

Mark Rogers Mark Rogers

Bearish

Pets at Home (PETS) shares rallied following FY26 results that showed early signs the retail turnaround may finally be gaining traction. Fourth quarter food volumes rose 3.7% after November price cuts, customer satisfaction improved by four points, and like for like sales returned to growth in the second half for the first time in two years. The company said its turnaround plan remains on track.

The market reaction was understandable because these were tangible improvements rather than purely optimistic guidance.

However, the key tension remains that stabilisation driven by lower pricing is not the same as a full recovery, yet the shares are beginning to trade as though management has already solved the deeper structural issues facing the business.

Retail’s recovery has a price attached – literally

Retail profit fell to £30.8 million from £72.9 million, with margins compressing to 2.4% from 5.6%. The second half recovery in volumes came after management reduced prices across 1,000 product lines by an average of 12%, which helped drive customer demand but came at a clear cost to profitability.

The company also completed a £20 million overhead reduction programme, although that represents a one off structural adjustment rather than a recurring source of savings. The challenge from here is where the next wave of efficiencies comes from as property costs, wage inflation, and logistics expenses continue to rise.

The real issue is not whether volumes can stabilise in the short term. It is whether Pets at Home can maintain that stability without relying on further discounting, and at this stage the answer remains uncertain.

What the dividend cut really says

The board “rebased” the dividend to 50% of earnings, effectively cutting the payout by 43% to 7.4p.

While the language framed this as a reset, the signal is harder to ignore, with management effectively indicating lower confidence in near term earnings growth.

If Bailey believed retail margins would recover back to 5% plus within two years, the dividend would likely have been temporarily reduced and then restored. Instead, it has been permanently reset to a lower level, which points to more cautious expectations for earnings recovery ahead.

The vet growth problem

Vet profit grew 10.4% to £83.8 million, with a 47.4% margin, while joint venture partners remain debt free and collected £48.1 million in distributions, a strong and highly cash generative business.

However, the company also disclosed that vet market growth is slowing as customer cohorts move into what it described as a “typical lull in activity.” The expansion phase that supported the group through FY25 and FY26 is now moderating, with average practice revenues rising just 3.9% in FY26.

The veterinary arm still generates around 90% of group free cash flow from roughly 35% of revenues, but as growth normalises, overall cash generation will slow unless retail margins recover meaningfully.

That brings the focus back to the core issue. Retail can defend volumes, but so far it has only done so by cutting price.

The valuation problem

At 199.80p, the shares trade on around 13.5x consensus FY27 earnings of £98 million, a valuation that assumes retail stabilisation holds and vet growth remains resilient despite ongoing structural pressure in the consumer business, while the analyst range of £90 million to £108 million highlights how uncertain that outcome still is.

If earnings land at £90 million rather than £98 million, the multiple rises to roughly 22x, which is not inexpensive for a business where one division effectively subsidises another and where a full margin recovery in retail has yet to be proven.

The company is comfortable with consensus expectations for FY27, which is reassuring in tone, although comfort is not the same as conviction, and even consensus assumes no further deterioration in retail conditions from here.

Why the downside is sharper

If retail margins stabilise at 3–4% and vet growth slows to low single digits, earnings likely muddle through and the shares sit around fair value at current levels, which broadly reflects the base case the market is pricing in.

The downside case is more pronounced, with pricing elasticity potentially re-emerging if volumes weaken under further discounting, consumer spending softening, or competitors reacting more aggressively, any of which would push retail margins lower again and leave group earnings under pressure, with limited protection built into the current valuation.

The upside case is more constrained, as a return to historical 5–6% retail margins would be meaningfully positive but would require either sustained volume growth without further price cuts, which is unproven, or a clear shift in product mix towards higher margin categories, which is also not yet evident, while the vet division ceiling is already visible in low single digit growth within a mature market.

One quarter doesn’t fix two years

The H2 turnaround is real and the firm’s execution has been credible, with the four pillar plan covering product, price, execution and cost delivering tangible results.

That matters, but one quarter of volume recovery driven by aggressive discounting is not enough to show that structural margin pressure has fully eased.

Discretionary accessories remain weak, pet ownership trends are normalising after the Covid period, and inflationary pressure across operating costs has not gone away.

PETS has stabilised the patient, but whether it can fully discharge her remains an open question.

Why the numbers fall short

Investors are paying 13.5x earnings for a group where the slower growing veterinary division generates most of the cash, while the larger retail division relies on price cuts to defend share.

That valuation is defensible if retail margins stabilise at 3–4% and vet growth holds in the low single digits, but it becomes more stretched if both conditions need to hold at the same time.

The shares are currently priced as though both outcomes are effectively secured, which is not yet supported by the underlying evidence.